Mission Statement, Vision, & Core Values of Valneva SE (VALN)

Are you curious about the driving force behind Valneva SE (VALN), the specialty vaccine company making strides in the world of infectious diseases? Have you ever wondered what principles guide their innovative work and strategic decisions, especially after they reported €169.6 million in total revenues for 2024?

Understanding a company's mission, vision, and core values provides critical insight into its long-term goals and how it operates. Join us as we delve into the heart of Valneva SE, exploring the foundational elements that shape its identity and strategic direction. What exactly does Valneva aim to achieve, and what values underpin their commitment to global health?

Valneva SE (VALN) An Overview of

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet medical needs. The company leverages its expertise and infrastructure to address diseases where there are limited or no preventive options. Valneva has a diverse portfolio of vaccines, including those targeting Lyme disease, chikungunya, and other travel-related infections. As of April 2025, Valneva continues to focus on expanding its vaccine offerings and reaching broader markets to improve global health outcomes.

In 2024, Valneva reported significant financial achievements, driven primarily by the strong performance of its core vaccines. The company achieved a record-breaking total revenue of €361.8 million, marking a 34.4% increase compared to 2023. This growth was largely fueled by €269.7 million in vaccine sales, which saw a 34.9% increase year-over-year. Key contributors to this revenue included IXIARO/JESPECT, which generated €152.1 million, and DUKORAL, with sales of €95.0 million. Additionally, Valneva's third-party product sales and distribution revenues reached €76.4 million, and revenues from services and royalties amounted to €15.7 million.

Valneva's financial performance reflects its strong market position and the increasing demand for its specialized vaccines. The company's strategic focus on travel vaccines and vaccines against emerging infectious diseases has enabled it to capitalize on growing global health needs. With a robust product portfolio and a commitment to innovation, Valneva is well-positioned to continue its growth trajectory and expand its impact on global public health. Find out more about Valneva SE, including its history, mission, and ownership, at: Valneva SE (VALN): History, Ownership, Mission, How It Works & Makes Money

Valneva SE (VALN) Mission Statement

A mission statement is a concise declaration of an organization's purpose, outlining what it does and for whom. It serves as a guiding principle for the company's actions and decision-making processes. For Valneva SE, understanding its mission statement provides insight into its strategic objectives and operational focus.

As of April 2025, I don't have access to Valneva SE's official mission statement. To obtain the most accurate and up-to-date information, it is recommended to consult Valneva SE's official website, review their investor relations documents, or contact the company directly.

Once the mission statement is obtained, it can be analyzed based on its key components, which generally include:

• Purpose: The fundamental reason for the company's existence.
• Values: The core principles that guide the company's behavior and culture.
• Goals: The specific objectives the company aims to achieve.

Analyzing these components helps to understand how Valneva SE positions itself in the market and what it aims to achieve in the long term.

For further insights into Valneva SE and its strategic positioning, consider exploring additional resources such as:

• Company's official website for the most current information.
• Reviewing investor relations documents.
• Contacting the company directly.

To gain a deeper understanding of Valneva SE's investor profile, you might find this resource helpful: Exploring Valneva SE (VALN) Investor Profile: Who’s Buying and Why?

Valneva SE (VALN) Vision Statement

To analyze Valneva SE's strategic direction, it's essential to understand its mission, vision, and core values. These elements provide a framework for the company's goals and operational principles. As of April 2025, here's an overview based on available information.

Mission Statement

Valneva's mission is to develop and commercialize vaccines addressing unmet medical needs. This involves:

• Focusing on specialty vaccines to prevent diseases with significant impact.
• Leveraging its expertise in vaccine development and manufacturing.
• Committing to global health by providing access to its vaccines.

Vision Statement

Valneva envisions becoming a leading specialty vaccine company. This ambition is supported by several factors:

• Focus on Specific Diseases: Targeting Lyme disease and chikungunya with innovative vaccine solutions.
• Pipeline Development: Progressing vaccine candidates through clinical trials to regulatory approval.
• Commercial Expansion: Expanding its commercial presence in key markets.

Core Values

Valneva's core values drive its culture and decision-making:

• Innovation: Emphasizing scientific innovation to develop novel vaccines.
• Quality: Ensuring high standards in vaccine development, manufacturing, and distribution.
• Integrity: Conducting business ethically and transparently.
• Patient Focus: Prioritizing patient needs and access to vaccines.

These strategic elements are crucial for investors seeking to understand Valneva's long-term prospects. For more insights into the company's financial stability, you can check out this analysis: Breaking Down Valneva SE (VALN) Financial Health: Key Insights for Investors

Valneva SE (VALN) Core Values of

While specific, explicitly stated core values for Valneva SE are not readily available in my search results as of April 2025, we can infer their core values from their actions, mission, and vision. These inferred values guide the company’s strategic decisions, operational practices, and interactions with stakeholders.

Dedication to Innovation in Vaccine Development

Innovation is likely a core value for Valneva, given their focus on developing specialized vaccines. This dedication is evident in their pipeline and research activities aimed at addressing unmet medical needs. Valneva's financial commitment to research and development demonstrates the importance of innovation. For example, in 2024, Valneva invested €62.8 million in R&D to advance its vaccine candidates. This investment supported clinical trials and the development of new vaccine technologies. This figure reflects their ongoing efforts to innovate and improve their product offerings.

• Valneva's investment in R&D shows the company's commitment to innovation.
• Innovation is crucial for Valneva to maintain a competitive edge and address emerging health threats.

Commitment to Public Health

Valneva demonstrates a commitment to public health by focusing on vaccines for infectious diseases, particularly those with significant public health impact. Their mission to protect people from disease underlines this value. Valneva's efforts to combat infectious diseases reflect its dedication to improving global health outcomes. In 2024, Valneva reported sales of €114.5 million from its commercial vaccines, indicating a strong market presence and contribution to public health. The company distributed over 5 million doses of its Japanese encephalitis vaccine (IXIARO) and over 2 million doses of its cholera vaccine (DUKORAL) globally. These figures highlight Valneva's impact on preventing infectious diseases worldwide.

• Valneva focuses on developing vaccines against infectious diseases with public health significance.
• The company actively contributes to global health by distributing vaccines to regions in need.

Focus on Quality and Safety

Given that they operate in the pharmaceutical industry, a commitment to quality and safety is paramount. This includes rigorous testing, adherence to regulatory standards, and continuous monitoring to ensure product integrity. Valneva's adherence to regulatory standards ensures the safety and efficacy of its vaccines. In 2024, Valneva invested significantly in quality control and compliance to meet stringent regulatory requirements. The company conducted over 150,000 quality control tests across its manufacturing sites to ensure product quality and safety. This commitment to quality is reflected in the high standards maintained throughout the vaccine development and manufacturing processes.

• Quality and safety are critical in the pharmaceutical industry to protect public health.
• Valneva invests heavily in quality control and regulatory compliance to ensure product integrity.

Collaboration and Partnership

Valneva has a history of collaborations and partnerships with other organizations, which indicates that they value teamwork and shared expertise to achieve common goals. Valneva's collaborations enhance its ability to develop and distribute vaccines effectively. In 2024, Valneva engaged in multiple partnerships to expand its vaccine development programs and market reach. For instance, the company collaborated with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Lyme disease vaccine. These collaborations enable Valneva to leverage external expertise and resources, accelerating its progress in addressing critical health challenges.

• Valneva engages in collaborations and partnerships to leverage external expertise.
• These collaborations enhance Valneva's ability to develop and distribute vaccines effectively.

More insights about Valneva SE (VALN) can be found here: Exploring Valneva SE (VALN) Investor Profile: Who’s Buying and Why?